ECONOMYNEXT – Sri Lanka’s cabinet has approved the implementation of the National Pharmaceutical Policy for 2026–2030 to ensure the supply of safe, effective, and affordable essential medicines, Minister Nalinda Jayatissa said.
The previous national policy, formulated in 2005, remained outdated after preliminary efforts to update it between 2020 and 2025 were not completed.
The new 2026–2030 framework addresses current health needs, global market changes, pharmaceutical supply chain disruptions, and new requirements for local medicine manufacturing, he said.
“This national policy is formulated to ensure an uninterrupted supply of high-quality medicines to the public and supply medicines at affordable prices to the market,” Jayatissa said.
Under the approved policy, the government aims to ensure that medicines comply with international quality standards and remain accessible at sustainable and fair prices, he claimed, and promotes the scientifically sound and cost-effective use of medical products by healthcare professionals and consumers to improve treatment quality and prevent wastage.
The framework also prioritizes the efficient domestic production of essential medical products with assured safety, efficacy, and quality.
“Encouraging and promoting local manufacturing of pharmaceuticals is one of the core objectives of the National Medicines Policy, and we are providing extensive facilities for this,” Jayatissa said.
The government has stipulated a Maximum Retail Price covering more than 1,000 medicine varieties across 60 categories, though price adjustments requested by importers due to exchange rate shifts remain pending because of an ongoing Court of Appeal hearing. (Colombo/Aug19/2026)